Page last updated: 2024-10-17

chlorine and Cough

chlorine has been researched along with Cough in 17 studies

chloride : A halide anion formed when chlorine picks up an electron to form an an anion.

Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.

Research Excerpts

ExcerptRelevanceReference
"The effect of a single, high dose of aspirin has been assessed against low chloride cough challenge."9.07The low-chloride cough response is not inhibited by a single, high dose of aspirin. ( Barnes, PJ; Fuller, RW; Stone, RA, 1992)
"The pH and chloride levels in exhaled breath condensate and capsaicin cough threshold (C5) were measured in 50 patients with chronic cough and in 16 healthy controls."5.11Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough. ( Chung, KF; Mann, B; Nguyen, LT; Niimi, A; Usmani, O, 2004)
"The effect of a single, high dose of aspirin has been assessed against low chloride cough challenge."5.07The low-chloride cough response is not inhibited by a single, high dose of aspirin. ( Barnes, PJ; Fuller, RW; Stone, RA, 1992)
" Using amiloride, a sodium ion blocker, and bumetanide, a blocker of the chloride ion co-transport system, the importance oftransepithelial sodium and chloride ion transport for support of the cough reflex was determined."3.75Ionic support of the cough reflex. ( Banach, B; Mikołajek-Bedner, W; Sroczyński, T; Słuczanowska-Glabowska, S, 2009)
" Common adverse events in part B included cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%])."2.82Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. ( Cooke, J; Cunningham, S; Davies, JC; Green, Y; Harris, WT; Lapey, A; Regelmann, WE; Robertson, S; Rosenfeld, M; Sawicki, GS; Southern, KW, 2016)
"Cough was then induced at 0."2.67Effect of frusemide on cough responses to chloride-deficient solution in normal and mild asthmatic subjects. ( Barnes, PJ; Chung, KF; Stone, RA, 1993)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19905 (29.41)18.7374
1990's5 (29.41)18.2507
2000's5 (29.41)29.6817
2010's1 (5.88)24.3611
2020's1 (5.88)2.80

Authors

AuthorsStudies
Yi, W1
Long, X1
Liu, J1
Shi, L1
Chen, Z1
Yang, J1
Yang, Z1
Lv, Z1
Fan, H1
Davies, JC1
Cunningham, S1
Harris, WT1
Lapey, A1
Regelmann, WE1
Sawicki, GS1
Southern, KW1
Robertson, S1
Green, Y1
Cooke, J1
Rosenfeld, M1
Banach, B2
Mikołajek-Bedner, W1
Sroczyński, T1
Słuczanowska-Glabowska, S1
Numasawa, T1
Shiba, K1
Nakazawa, K1
Umezaki, T1
Niimi, A1
Nguyen, LT1
Usmani, O1
Mann, B1
Chung, KF2
Lukela, M1
DeGuzman, D1
Weinberger, S1
Saint, S1
Mazzone, SB1
McGovern, AE1
Stone, RA2
Barnes, PJ3
Cavigioli, G1
Pelucchi, A1
Mastropasqua, B1
Chiesa, M1
Marazzini, L1
Foresi, A1
Tyrakowski, T1
Wojciechowska, I1
Mościbroda, A1
Greczko, I1
Nyitray, L1
Fuller, RW2
Stone, R1
Godden, DJ1
Borland, C1
Lowry, R1
Higenbottam, TW1
Higenbottam, T1
McCombs, ML1
Gecse, A1
Zsilinszky, E1
Lonovics, J1
West, GB1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation[NCT01705145]Phase 335 participants (Actual)Interventional2013-01-31Completed
Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux[NCT00451841]30 participants (Anticipated)Observational2007-03-31Terminated (stopped due to IRB approval not renewed/approval lapsed. Prior status: insufficient enrollment; study suspended pending analysis)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24

BMI = (Weight [in kg]) divided by (Stature [in meters])^2. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Baseline, Week 24

Interventionkilogram per square meter (kg/m^2) (Mean)
Part B: Ivacaftor 50 mg0.332
Part B: Ivacaftor 75 mg0.314
Part B: Overall Ivacaftor0.319

Part B: Absolute Change From Baseline in Stature at Week 24

Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventioncentimeters (cm) (Mean)
Part B: Ivacaftor 50 mg2.5
Part B: Ivacaftor 75 mg3.5
Part B: Overall Ivacaftor3.3

Part B: Absolute Change From Baseline in Sweat Chloride at Week 24

Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventionmillimole per liter (mmol/L) (Mean)
Part B: Ivacaftor 50 mg-47.07
Part B: Ivacaftor 75 mg-46.78
Part B: Overall Ivacaftor-46.86

Part B: Absolute Change From Baseline in Weight at Week 24

Data was reported as per the dose received and for overall participants. (NCT01705145)
Timeframe: Part B: Baseline, Week 24

Interventionkilograms (kg) (Mean)
Part B: Ivacaftor 50 mg1.00
Part B: Ivacaftor 75 mg1.50
Part B: Overall Ivacaftor1.36

Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants." (NCT01705145)
Timeframe: Part A: Up to 93 Days

,,
Interventionparticipants (Number)
AEsSAEsRelated AEs
Part A: Ivacaftor 50 mg301
Part A: Ivacaftor 75 mg503
Part A: Overall Ivacaftor804

Part A: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor [M1] and ivacaftor carboxylate [M6]) up to 24 hours post-dose on Day 4 (Hour 0 [pre-dose] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part A: up to 24 hours post-dose on Day 4

Interventionnanogram per milliliter (ng/mL) (Mean)
Ivacaftor: Hour 0 on Day 1Ivacaftor: Hour 0 on Day 4Ivacaftor: 2 Hours Post-Dose on Day 4Ivacaftor: 3 Hours Post-Dose on Day 4Ivacaftor: 6 Hours Post-Dose on Day 4Ivacaftor: 24 Hours Post-Dose on Day 4M1: Hour 0 on Day 1M1: Hour 0 on Day 4M1: 2 Hours Post-Dose on Day 4M1: 3 Hours Post-Dose on Day 4M1: 6 Hours Post-Dose on Day 4M1: 24 Hours Post-Dose on Day 4M6: Hour 0 on Day 1M6: Hour 0 on Day 4M6: 2 Hours Post-Dose on Day 4M6: 3 Hours Post-Dose on Day 4M6: 6 Hours Post-Dose on Day 4M6: 24 Hours Post-Dose on Day 4
Part A: Overall Ivacaftor0.003967269575421240.0012401540231015803890.001150105013001390439

Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs

"AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event.~Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received." (NCT01705145)
Timeframe: Part B: Up to 28 Weeks

,,
Interventionparticipants (Number)
AEsSAEsRelated AEs
Part B: Ivacaftor 50 mg1033
Part B: Ivacaftor 75 mg2338
Part B: Overall Ivacaftor33611

Part B: Plasma Concentration of Ivacaftor and Its Metabolites

Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 [predose] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period. (NCT01705145)
Timeframe: Part B: up to 24 hours post-dose on Day 168

Interventionng/mL (Mean)
Ivacaftor: Hour 0 on Day 1Ivacaftor: Hour 0 on Day 14Ivacaftor: 2 Hours Post-Dose on Day 14Ivacaftor: 3 Hours Post-Dose on Day 14Ivacaftor: 6 Hours Post-Dose on Day 14Ivacaftor: Hour 0 on Day 56Ivacaftor: 1 Hour Post-Dose on Day 56Ivacaftor: Hour 0 on Day 112Ivacaftor: 4 Hours Post-Dose on Day 112Ivacaftor: 6 Hours Post-Dose on Day 112Ivacaftor: Hour 0 on Day 168Ivacaftor: 24 Hours Post-Dose on Day 168M1: Hour 0 on Day 1M1: Hour 0 on Day 14M1: 2 Hours Post-Dose on Day 14M1: 3 Hours Post-Dose on Day 14M1: 6 Hours Post-Dose on Day 14M1: Hour 0 on Day 56M1: 1 Hour Post-Dose on Day 56M1: Hour 0 on Day 112M1: 4 Hours Post-Dose on Day 112M1: 6 Hours Post-Dose on Day 112M1: Hour 0 on Day 168M1: 24 Hours Post-Dose on Day 168M6: Hour 0 on Day 1M6: Hour 0 on Day 14M6: 2 Hours Post-Dose on Day 14M6: 3 Hours Post-Dose on Day 14M6: 6 Hours Post-Dose on Day 14M6: Hour 0 on Day 56M6: 1 Hour Post-Dose on Day 56M6: Hour 0 on Day 112M6: 4 Hours Post-Dose on Day 112M6: 6 Hours Post-Dose on Day 112M6: Hour 0 on Day 168M6: 24 Hours Post-Dose on Day 168
Part B: Overall Ivacaftor0.0061493210801140448514596108010105002070.0015801870228026701340117016802450250014606020.001520143016302090151013101660181021301520632

Reviews

1 review available for chlorine and Cough

ArticleYear
Research in cystic fibrosis: a review.
    Texas reports on biology and medicine, 1973,Winter, Volume: 31, Issue:4

    Topics: Biological Transport; Calcium; Cells, Cultured; Child; Chlorides; Cough; Cystic Fibrosis; Digestive

1973

Trials

6 trials available for chlorine and Cough

ArticleYear
Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
    The Lancet. Respiratory medicine, 2016, Volume: 4, Issue:2

    Topics: Aminophenols; Child, Preschool; Chloride Channel Agonists; Chlorides; Cough; Cystic Fibrosis; Cystic

2016
Reduced pH and chloride levels in exhaled breath condensate of patients with chronic cough.
    Thorax, 2004, Volume: 59, Issue:7

    Topics: Adult; Asthma; Breath Tests; Bronchiectasis; Capsaicin; Chlorides; Chronic Disease; Cough; Female; G

2004
Effect of frusemide on cough responses to chloride-deficient solution in normal and mild asthmatic subjects.
    The European respiratory journal, 1993, Volume: 6, Issue:6

    Topics: Adult; Asthma; Bronchial Provocation Tests; Chlorides; Cough; Double-Blind Method; Female; Forced Ex

1993
The low-chloride cough response is not inhibited by a single, high dose of aspirin.
    British journal of clinical pharmacology, 1992, Volume: 34, Issue:4

    Topics: Aspirin; Bicarbonates; Chlorides; Cough; Double-Blind Method; Humans; Sodium; Sodium Bicarbonate

1992
Contrasting effects of prostaglandins E2 and F2 alpha on sensitivity of the human cough reflex.
    Journal of applied physiology (Bethesda, Md. : 1985), 1992, Volume: 73, Issue:2

    Topics: Adolescent; Adult; Capsaicin; Chlorides; Citrates; Citric Acid; Cough; Dinoprost; Dinoprostone; Doub

1992
Chemical specificity of coughing in man.
    Clinical science (London, England : 1979), 1986, Volume: 70, Issue:3

    Topics: Acetates; Acetic Acid; Administration, Intranasal; Adolescent; Adult; Aerosols; Bicarbonates; Chlori

1986

Other Studies

10 other studies available for chlorine and Cough

ArticleYear
Risk factors for recurrent positive results of the nucleic acid amplification test for COVID-19 patients: a retrospective study.
    Human cell, 2021, Volume: 34, Issue:6

    Topics: Adult; Aged; Chlorides; Cough; COVID-19; COVID-19 Nucleic Acid Testing; False Positive Reactions; Fe

2021
Ionic support of the cough reflex.
    Annales Academiae Medicae Stetinensis, 2009, Volume: 55, Issue:3

    Topics: Amiloride; Animals; Bumetanide; Chlorides; Cough; Female; In Vitro Techniques; Ion Transport; Male;

2009
Membrane potential changes in vocal cord tensor motoneurons during breathing, vocalization, coughing and swallowing in decerebrate cats.
    Neuroscience research, 2004, Volume: 49, Issue:3

    Topics: Analysis of Variance; Animals; Cats; Chlorides; Cough; Decerebrate State; Deglutition; Female; Male;

2004
Clinical problem-solving. Unfashionably late.
    The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1

    Topics: Adolescent; Biopsy; Burkholderia cepacia; Burkholderia Infections; Chest Pain; Chlorides; Cough; Cys

2005
Na+-K+-2Cl- cotransporters and Cl- channels regulate citric acid cough in guinea pigs.
    Journal of applied physiology (Bethesda, Md. : 1985), 2006, Volume: 101, Issue:2

    Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Chloride Channels; Chlorides; Citric Acid

2006
Prevalence and repeatability of the cough response induced by inhalation of low chloride ion solutions in normal subjects.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 1995, Volume: 50, Issue:5

    Topics: Administration, Inhalation; Adolescent; Adult; Chlorides; Cough; Female; Forced Expiratory Volume; H

1995
[Electrophysiologic studies of local ion transport changes in the tracheal wall in vitro].
    Annales Academiae Medicae Stetinensis, 1997, Volume: 43

    Topics: Amiloride; Animals; Bumetanide; Chi-Square Distribution; Chlorides; Cough; Epithelium; Gagging; In V

1997
[Analysis of antitussive syrup for the use of diabetics].
    Acta pharmaceutica Hungarica, 1977, Volume: 47, Issue:1

    Topics: Antitussive Agents; Chlorides; Codeine; Cough; Diabetes Mellitus; Drug Stability; Humans; Sorbitol

1977
The ionic composition of airway surface liquid and coughing.
    Bulletin europeen de physiopathologie respiratoire, 1987, Volume: 23 Suppl 10

    Topics: Aerosols; Bronchi; Chemoreceptor Cells; Chlorides; Cough; Epithelium; Glucose; Humans; Hydrogen-Ion

1987
C-phenylglycine-n-heptyl ester as an inhibitor of mediators of allergic reactions.
    International archives of allergy and applied immunology, 1971, Volume: 41, Issue:1

    Topics: Acetylcholine; Aerosols; Anaphylaxis; Animals; Antigens; Barium; Bradykinin; Chlorides; Cough; Drug

1971